Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - clobazam 10mg - tablet - 10 mg - active: clobazam 10mg excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate maize starch purified talc - adjunctive therapy in partial or generalised epilepsy and monotherapy in certain forms of epilepsy such as lennox-gastaut and catamenial epilepsy.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - zopiclone 7.5mg; zopiclone 7.5mg - film coated tablet - 7.5 mg - active: zopiclone 7.5mg excipient: calcium hydrogen phosphate dihydrate ethanol hypromellose lactose monohydrate magnesium stearate purified water   sodium starch glycolate titanium dioxide wheat starch active: zopiclone 7.5mg excipient: calcium hydrogen phosphate dihydrate lactose monohydrate magnesium stearate opadry white oy-s-38906 purified water   sodium starch glycolate wheat starch - zopiclone is indicated for the short-term treatment of insomnia in adults.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - azathioprine 50mg;   - film coated tablet - 50 mg - active: azathioprine 50mg   excipient: hypromellose lactose monohydrate macrogol 400 magnesium stearate opaspray orange m-1-23104 purified water starch stearic acid - imuran is used as an immunosuppressant antimetabolities, either alone or, more commonly in combination with other agents (usually corticosteroids) and procedures which influence the immune response. therapeutic effect may be evident only after weeks or months and can include a steroid-sparing effect, thereby reducing the toxicity associated with high dosage and prolonged usage of corticosteroids. imuran, in combination with corticosteroids and/or other immunosuppressive agents and procedured, is indicated to enhance the survival of organ transplants, such as renal transplants, cardiac transplants, and hepatic transplants; and to reduce the corticosteroid requirements of renal transplant recipients. imuran is indicated in the treatment of moderate to severe crohn's disease in patients in whom corticosteroid therapy is required, in patients who cannot tolerate corticosteroid therapy, or in patients whose disease is refractory to other standard first line therapy. imuran, either alone or more usually in combination with corticosteroids and/or other medicines and procedures, has been used with clinical benefit (which may include reduction of dosage or discontinuation of corticosteroids) in a proportion of patients suffering from the following: · severe rheumatoid arthritis · systemic lupus erythematosus · dermatomyositis and polymyositis · auto-immune chronic active hepatitis · permphigus vulgaris · polyarteritis nodosa · auto-immune haemolytic anaemia · chronic refractory idiopathic thrombocytopenic purpura · ulcerative colitis

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - azathioprine 50mg (as freeze-dried sodium salt);   - powder for injection - 50 mg - active: azathioprine 50mg (as freeze-dried sodium salt)   excipient: sodium hydroxide - imuran is used as an immunosuppressant antimetabolities, either alone or, more commonly in combination with other agents (usually corticosteroids) and procedures which influence the immune response. therapeutic effect may be evident only after weeks or months and can include a steroid-sparing effect, thereby reducing the toxicity associated with high dosage and prolonged usage of corticosteroids. imuran, in combination with corticosteroids and/or other immunosuppressive agents and procedured, is indicated to enhance the survival of organ transplants, such as renal transplants, cardiac transplants, and hepatic transplants; and to reduce the corticosteroid requirements of renal transplant recipients. imuran is indicated in the treatment of moderate to severe crohn's disease in patients in whom corticosteroid therapy is required, in patients who cannot tolerate corticosteroid therapy, or in patients whose disease is refractory to other standard first line therapy. imuran, either alone or more usually in combination with corticosteroids and/or other medicines and procedures, has been used with clinical benefit (which may include reduction of dosage or discontinuation of corticosteroids) in a proportion of patients suffering from the following: · severe rheumatoid arthritis · systemic lupus erythematosus · dermatomyositis and polymyositis · auto-immune chronic active hepatitis · permphigus vulgaris · polyarteritis nodosa · auto-immune haemolytic anaemia · chronic refractory idiopathic thrombocytopenic purpura · ulcerative colitis

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - irinotecan hydrochloride trihydrate 20 mg/ml ((equivalent to 17.33 mg irinotecan));   - solution for infusion - 20 mg/ml - active: irinotecan hydrochloride trihydrate 20 mg/ml ((equivalent to 17.33 mg irinotecan))   excipient: hydrochloric acid lactic acid sodium hydroxide sorbitol water for injection - irinotecan hydrochloride trihydrate injection is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum, in combination with 5fu/leucovorin. irinotecan hydrochloride trihydrate injection is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - digoxin 0.25mg;  ;  ;  ;  ; digoxin 0.25mg - tablet - 0.25 mg - active: digoxin 0.25mg         excipient: lactose monohydrate magnesium stearate maize starch pregelatinised maize starch purified water rice starch active: digoxin 0.25mg excipient: lactose monohydrate magnesium stearate maize starch purified water rice starch starch, oxidised - cardiac failure:- lanoxin is indicated in the management of chronic cardiac failure where the dominant problem is systolic dysfunction. its therapeutic benefit is greatest in those patients with ventricular dilatation. lanoxin is specifically indicated where cardiac failure is accompanied by atrial fibrillation. supraventricular arrhythmias:- lanoxin is indicated in the management of certain supraventricular arrhythmias, particularly atrial flutter and fibrillation, where a major beneficial effect is reduction of the ventricular rate.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - digoxin 0.05 mg/ml;   - elixir - 0.05 mg/ml - active: digoxin 0.05 mg/ml   excipient: citric acid monohydrate dibasic sodium phosphate ethanol lime flavour 70.80.0303 methyl hydroxybenzoate propylene glycol purified water quinoline yellow sucrose - lanoxin is indicated in the management of chronic cardiac failure where the dominant problem is systolic dysfunction. its therapeutic benefit is greatest in those patients with ventricular dilatation. lanoxin is specifically indicated where cardiac failure is accompanied by atrial fibrillation.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - digoxin 0.0625mg;  ;  ;  ;  ; digoxin 0.0625mg - tablet - 0.0625 mg - active: digoxin 0.0625mg         excipient: indigo carmine lactose monohydrate magnesium stearate maize starch povidone pregelatinised maize starch purified water rice starch active: digoxin 0.0625mg excipient: indigo carmine lactose monohydrate magnesium stearate maize starch povidone purified water rice starch starch, oxidised - cardiac failure:- lanoxin is indicated in the management of chronic cardiac failure where the dominant problem is systolic dysfunction. its therapeutic benefit is greatest in those patients with ventricular dilatation. lanoxin is specifically indicated where cardiac failure is accompanied by atrial fibrillation. supraventricular arrhythmias:- lanoxin is indicated in the management of certain supraventricular arrhythmias, particularly atrial flutter and fibrillation, where a major beneficial effect is reduction of the ventricular rate.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - tioguanine 40mg - tablet - 40 mg - active: tioguanine 40mg excipient: acacia lactose monohydrate magnesium stearate potato starch stearic acid - lanvis is indicated primarily for the treatment of acute leukaemias especially:- · acute myelogenous leukaemia · acute lymphoblastic leukaemia

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - chlorpromazine hydrochloride 10mg - tablet - 10 mg - active: chlorpromazine hydrochloride 10mg excipient: colloidal silicon dioxide hypromellose lactose monohydrate macrogol 200 magnesium stearate maize starch opaspray white m-1-7111b purified water